Get a deeper insight into the potential performance of Cognizant (CTSH) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some ...

Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX ...

TSMC holds a crucial place in the semiconductor supply chain, and 24/7 Wall St. projects a substantial gain for the stock by ...

Key Points - Revenue (non-GAAP) topped expectations at $506 million for Q2 FY2025, rising 15% year over year and beating consensus by 3.5 %. Non-GAAP earnings per share hit $0.13 for Q2 FY2025, ...